Edition:
United States

Sunovion’s Latuda receives Health Canada approval to treat adolescents with schizophrenia


Friday, 21 Jul 2017 12:10pm EDT 

July 21 (Reuters) - Sumitomo Dainippon Pharma Co Ltd <4506.T>:Sunovion’s Latuda® (lurasidone HCI) receives Health Canada approval to treat adolescents with schizophrenia.Sunovion's Latuda receives Health Canada approval to treat adolescents with schizophrenia.